Levocarnitine

Quick links to important sections

Levocarnitine

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levocarnitine

Levocarnitine: A Core Identity and Classification

Property Description
Active ingredient Levocarnitine (L-carnitine)
Form Oral solution, tablet, capsule, sterile injection
Pharmacological class Amino acid derivative, Carnitine replacement therapy agent
General purpose Metabolic support, energy pathway restoration
Origin Endogenous substance (pharmaceutically synthetic)

Levocarnitine is a prescription medication that functions as an amino acid derivative and a crucial essential cofactor for human metabolism. This compound is the biologically active form of L-carnitine, the specific stereoisomer utilized by the body. Pharmacologically, it is classified as a carnitine replacement therapy agent. While L-carnitine is a naturally occurring substance required in the body, the therapeutic version is produced synthetically to ensure purity and precise consistency.

Composition, Pharmaceutical Forms, and Essential Function

The medicine is supplied as a single-ingredient product, containing the active ingredient Levocarnitine and necessary excipients. To accommodate different clinical requirements, the product is available in multiple dosage forms for both oral and intravenous (IV) routes of administration, including an oral solution, tablet, capsule, and a sterile aqueous solution for injection. Levocarnitine's essential function is to serve as a shuttle system that facilitates the transport of long-chain fatty acids into the cell's mitochondria, where they are converted into energy.

General Purpose of Levocarnitine Therapy

The primary goal of administering Levocarnitine is to address metabolic deficiencies by replenishing the body's supply of this compound when it is inadequate due to inherited or acquired conditions. This replacement therapy helps maintain the integrity of the cellular machinery necessary for energy production and aids in the detoxification process. In specific clinical settings, such as chronic hemodialysis, Levocarnitine is used to manage secondary carnitine deficiencies and support metabolic balance.

Regulatory References

  1. NIH ODS Fact Sheet: Carnitine

What side effects are possible with Levocarnitine?

Levocarnitine: Possible Side Effects and Safety Information

This safety information reflects the adverse reactions and considerations explicitly documented in official regulatory sources, such as FDA and EMA labeling.


Documented Adverse Reactions

Side effects reported as Common in regulatory labeling primarily involve the Gastrointestinal System, including nausea, vomiting, abdominal cramps, and diarrhea. These effects are often associated with the oral route of administration, and label documents note that decreasing the dosage often helps to diminish them.

A distinct metabolic event documented in the safety profile is a drug-related body odor which, along with the common gastrointestinal effects, may be associated with chronic long-term administration of the oral solution.


Serious Reactions and Population-Specific Safety

Serious Hypersensitivity Reactions, including anaphylaxis, laryngeal edema, and bronchospasm, have been reported, primarily following intravenous administration and most often in patients with End-Stage Renal Disease (ESRD) undergoing dialysis. The regulatory label also documents reports of seizures and an increase in the frequency and/or severity of seizures in patients with pre-existing seizure disorders.

Specific safety considerations apply to certain populations:

Population Regulatory Safety Note
Renal Impairment Chronic oral use may lead to the accumulation of metabolites (TMA/TMAO), contributing to body odor.
Diabetic Patients Use may result in hypoglycemia due to enhanced glucose utilization.
Warfarin Users Reports of increased International Normalised Ratio (INR) exist; coagulation monitoring is specified in official documents.

Safety documents also specify that too rapid consumption of the oral solution may trigger gastrointestinal reactions. The safety of the medicine during pregnancy and lactation is assessed against the potential benefit, due to a lack of adequate and well-controlled studies.

Overdose and Emergency Response

The regulatory overdose profile for Levocarnitine is defined by the official statement that no reports of toxicity from acute overdosage have been formally documented. However, exposure to unusually large doses is associated with gastrointestinal disturbances.

Official Management and Specific Risks

Area Regulatory Statement
Acute Manifestations Diarrhea is the documented gastrointestinal manifestation occurring with large doses.
Antidote/Management Overdosage is managed with supportive care; Levocarnitine is easily removed from plasma by dialysis, a recognized procedure for excess removal.
Specific Chronic Risk The chronic administration of high oral doses to patients with severely compromised renal function or those on ESRD dialysis carries a specific risk. This may lead to the accumulation of metabolites, including trimethylamine (TMA), which can potentially cause neurophysiologic effects.

When Urgent Medical Attention is Required

While acute overdose toxicity is not reported, the labeling requires patients to seek medical attention immediately if they experience symptoms suggestive of a severe hypersensitivity reaction. This includes life-threatening events such as laryngeal edema, bronchospasm, or anaphylaxis. These are serious adverse reactions that necessitate the discontinuation of the drug and the initiation of appropriate medical treatment, as mandated by regulatory authorities for severe reactions documented in the prescribing information.

Therapeutic Uses of Levocarnitine

Levocarnitine is used in conditions that may lead to serious systemic problems affecting the heart, liver, and muscles.

The medicine is relevant for easing symptom clusters that may become intense or disruptive in conditions presenting with inherited carnitine deficiencies, acquired deficiencies like those from End-Stage Renal Disease (ESRD) in dialysis patients, and certain organic acidemias. This treatment is primarily applied to support symptoms related to systemic imbalance and to address symptoms related to heightened physiological activity.

The therapy is relevant for easing chronic fatigue, muscular weakness (hypotonia), and assisting with the management of related cardiomyopathy. It is also commonly used to help with metabolic stabilization during acute episodes like sudden hypoglycemia.

It provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Metabolic Symptoms
This replacement therapy is considered relevant in clinical settings involving acute or unstable symptom patterns, such as crises linked to inherited metabolic diseases, where it contributes to improved comfort and helps ease the overall symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Levocarnitine?

Eligibility for Levocarnitine use is strictly defined by regulatory documents, focusing on patient status and specific pre-existing conditions.

Eligibility Status

Status Applicable Population Group Regulatory Basis
Allowed Patients with primary systemic carnitine deficiency. Patients with secondary carnitine deficiency due to inborn errors of metabolism. ESRD patients undergoing maintenance hemodialysis for associated deficiency. Established Indication
Contraindicated Patients with known hypersensitivity to Levocarnitine or any excipients. Patients with rare hereditary problems, such as fructose intolerance, must avoid certain oral solutions. Absolute Exclusion

Population-Specific Restrictions

  • Age Groups: Pediatric use is established, including for infants and newborns with carnitine deficiencies. No specific restrictions are noted for the geriatric population.
  • Renal Function: Chronic, high-dose oral use is not recommended in patients with severely compromised renal function due to the potential for metabolite accumulation. The safety of oral Levocarnitine is not established for general renal insufficiency.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed, lacking adequate controlled studies. Use during lactation requires careful consideration of risk versus benefit to the child.
  • Comorbidities: Caution is required for patients with pre-existing seizure activity (risk of increased seizure frequency) and diabetic patients (risk of hypoglycemia).

What should I know about interactions with other medicines?

Levocarnitine Interactions with other medicines and products

Official regulatory documents define the interaction profile of levocarnitine by highlighting specific risks associated with certain co-administered substances and patient populations. This profile is governed by pharmacodynamic outcomes and population-dependent exposure constraints, rather than extensive enzyme-mediated (CYP450) or transporter-based interactions.

Documented Interactions and Constraints

Interaction Type Interacting Substance/Condition Official Regulatory Outcome
Drug-Drug (Pharmacodynamic) Warfarin (and related Vitamin K Antagonists) Co-administration is associated with reports of an increase in International Normalized Ratio (INR).
Drug-Substance (Restriction) D-carnitine and DL-carnitine forms These non-pharmaceutical forms are officially noted to interfere with the intended biological action of levocarnitine.
Population-Dependent Exposure Patients with severely compromised renal function or ESRD on dialysis Reduced renal clearance leads to the accumulation of metabolites (trimethylamine and trimethylamine-N-oxide).

Official prescribing information does not list any medicines that are formally classified as contraindicated for co-administration with levocarnitine. Furthermore, no mandatory timing rules or separation requirements for administration are specified in the official regulatory documents. There are no documented interaction patterns with food, drinks, or alcohol.

Mechanism of Action

Core Mechanism: Cofactor and Transport for Fatty Acids

The primary function of Levocarnitine is to serve as a cofactor and carrier molecule utilized by the Carnitine Palmitoyltransferase (CPT) shuttle system. This mechanism facilitates the specific transport of long-chain fatty acids across the inner mitochondrial membrane and into the matrix . Levocarnitine is required to activate and transport these substrates for subsequent beta-oxidation.

Augmentation of Cellular Bioenergetics (ATP Synthesis)

By ensuring the steady, efficient delivery of fatty acids to the mitochondria, Levocarnitine directly augments the beta-oxidation pathway. This leads to enhanced production of acetyl-CoA, which in turn supports the synthesis of Adenosine Triphosphate (ATP). This increased cellular energy supply, or bioenergetic flux, occurs in high-energy-demand tissues such as the myocardium and skeletal muscles.

️ Conversion and Export of Toxic Acyl-CoA Metabolites

Levocarnitine facilitates the conversion and export of accumulated acyl-CoA esters, which can interfere with essential enzyme functions. This mechanism utilizes the CPT-I system to bind these intermediates, turning them into less reactive acylcarnitines for removal. This process supports metabolite homeostasis, which is a functional consequence that complements the pathway's effect on energy synthesis.

Dosage and Administration Information

Levocarnitine usage is guided by the official route of administration, which is selected based on the patient's clinical state. For chronic, long-term carnitine replacement therapy, the oral route is used, with the medicine available as a tablet or an oral solution. The oral solution may be consumed alone or mixed with liquid foods, but should be consumed slowly over a period of several minutes to enhance tolerance. In cases of acute metabolic crisis or for treatment in patients with carnitine deficiency secondary to hemodialysis, the drug is administered via the intravenous (IV) route as a sterile injection.

Administration Type Dosing Pattern Key Timing Rule
Oral Maintenance Up to 3 g daily, divided into multiple doses. Taken during or immediately following meals.
IV Acute Crisis Initial 50 mg/kg loading dose. Repeated every 3 to 6 hours; administered as a slow 2–3 minute bolus.

The oral regimen requires the total daily dose to be spaced evenly throughout the day to optimize absorption. For pediatric patients, the oral dose is calculated based on weight, typically ranging from 50 mg/kg/day to 100 mg/kg/day in divided doses. When used in hemodialysis, the intravenous dose is 10 mg/kg to 20 mg/kg of dry body weight, administered specifically as a slow bolus after each dialysis session. All therapeutic courses require periodic monitoring of plasma free carnitine levels to guide dose adjustments and ensure the therapeutic range is maintained.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levocarnitine

Levocarnitine was studied for its use when the body's natural carnitine levels are low due to underlying metabolic conditions or organ failure. Understanding the research involves looking at what kinds of studies were conducted, what they measured, and what findings were described in a neutral way, without making claims about individual outcomes.


Evidence for Use in Inherited Metabolic Disorders

This section summarizes the clinical trials, observational data, and case reports relevant to the evaluation of Levocarnitine’s use for patients with confirmed primary or secondary carnitine deficiencies.

For conditions characterized by fluctuating or episodic manifestations linked to inherited defects, Levocarnitine was evaluated in studies that included infants, children, and adults. Research examined how the use of Levocarnitine was associated with the normalization of blood carnitine levels in the observed populations. For certain severe genetic disorders, research describes patterns observed in the studies related to the frequency of acute metabolic decompensation events. Research relevant to the physiological role of carnitine focuses on these specific deficiencies.


Evidence for Use in Patients Undergoing Chronic Dialysis

This part outlines the findings from randomized controlled trials (RCTs) and systematic reviews that have investigated Levocarnitine's effect on common symptoms and blood markers related to acquired carnitine deficiency in patients with End-Stage Renal Disease (ESRD).

Studies monitored patient-reported outcomes describing perceived discomfort related to physical energy and muscle function. The reported patterns on subjective symptoms were mixed across many trials. Some evidence was observed in some studies regarding patterns related to erythropoietin-stimulating agent doses or hemoglobin levels in certain dialysis patient subgroups. However, a comprehensive analysis of multiple RCTs suggests that the overall evidence related to patient-reported outcomes describing perceived discomfort is not fully established.


Unanswered Questions and Research Gaps

The evidence quality varies across studies, leading to some areas of uncertainty. Follow-up durations were limited in many controlled trials, leaving gaps in the understanding of how long the reported patterns observed in the studies might last. The research focusing on systemic markers (inflammation) is often limited and heterogeneous, and the findings were mixed across different health conditions.

Key Studies & References

  1. L-Carnitine: Fact Sheet for Health Professionals - NIH Office of Dietary Supplements
  2. Efficacy of L-carnitine on clinical and biochemical parameters in patients with hemodialysis: A systematic review and meta-analysis of randomized controlled trials
  3. Carnitine Palmitoyltransferase II Deficiency (CPT II) - GeneReviews®
  4. Effects of L-carnitine on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Levocarnitine (FAQ)


Q: What happens if I forget to take my Levocarnitine dose?

If a dose of Levocarnitine is missed, regulatory patient guidance indicates it can be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, patient instructions indicate the missed dose should be skipped to prevent taking a double dose. This guidance helps maintain the regular dosing schedule.


Q: Does Levocarnitine interact with common blood thinners?

Official regulatory documents specifically highlight that taking Levocarnitine alongside the blood thinner Warfarin is associated with reports of an increase in International Normalized Ratio (INR), which measures how long it takes blood to clot. For patients using Warfarin, regulatory documents specify that careful monitoring of coagulation status is required. Regulatory information does not list restrictions or mandatory monitoring for other common blood thinners.


Q: Can I take Levocarnitine if I have thyroid problems?

Official drug documents do not list thyroid problems as a contraindication, meaning the medicine is not strictly forbidden for this patient group. However, some scientific research has noted that L-carnitine and thyroid hormone may interact reciprocally, which means they could influence each other's activity in the body.


Q: Can Levocarnitine interfere with my diabetes medication?

Regulatory safety information warns that the use of Levocarnitine in diabetic patients may result in hypoglycemia (low blood sugar) because of enhanced glucose utilization. Regulatory guidance specifies that specific monitoring of blood glucose levels may be required for diabetic patients.


Q: What should I do if I notice a change in body odor while on Levocarnitine?

A drug-related body odor is a documented adverse reaction, particularly associated with the oral solution taken long-term. For related side effects like gastrointestinal discomfort, regulatory documents note that decreasing the dosage often helps to diminish the effect. Regulatory documents indicate that this concern is subject to review by the prescribing healthcare provider.


Q: Can Levocarnitine be taken with over-the-counter pain relievers?

Official regulatory information does not list any medicines, including non-prescription or over-the-counter pain relievers, that are formally classified as contraindicated for co-administration with Levocarnitine. This indicates no known specific drug restrictions apply for these medications.


Q: What is the difference between the oral solution and the injection form?

The difference lies in the purpose and method of administration. The oral solution is typically used for chronic, long-term carnitine replacement. In contrast, the sterile injection (intravenous form) is administered as a slow bolus for acute medical situations, such as metabolic crises or deficiency secondary to hemodialysis.


Q: Can I take Levocarnitine if I have seizures?

Regulatory documents note that caution is advised for patients with pre-existing seizure activity due to reports of an increase in the frequency and/or severity of seizures in some patients. Official documents specify that close monitoring during treatment is required for patients with a history of seizures.


Q: Are there any long-term side effects of taking Levocarnitine?

Regulatory safety documents note that certain side effects may be associated with chronic long-term administration. These documented effects include a drug-related body odor and common gastrointestinal side effects.


Q: Do children take the same kind of Levocarnitine as adults?

Both children and adults may use the same available pharmaceutical forms, which include the oral solution and tablets. While the kind of medicine is the same, the dosage for children is carefully calculated based on their body weight, according to official guidance.


Q: Is Levocarnitine safe to take during pregnancy or while breastfeeding?

Official prescribing information states that use during pregnancy is permitted only if clearly needed, due to a lack of adequate controlled studies. Similarly, use during lactation requires careful consideration of the potential risk versus benefit to the child.


Q: How does Levocarnitine affect the metabolism?

The drug is classified as a carnitine replacement therapy agent. Its function is to support metabolism by serving as a cofactor that helps transport long-chain fatty acids into the mitochondria, which are the energy-producing centers of the cell. This process supports the efficient generation of cellular energy.


Q: Is Levocarnitine a vitamin or a mineral?

Levocarnitine is neither classified as a vitamin nor a mineral. It is an amino acid derivative and a crucial essential cofactor for human metabolism. It is the biologically active form of the naturally occurring substance known as L-carnitine.


Q: Does taking Levocarnitine affect lab test results?

Official documents specify that plasma free carnitine levels must be monitored periodically to guide dose adjustments. Coagulation monitoring is also specified for patients taking warfarin. The drug has also been reported in studies to influence certain other biochemical markers.


Q: Is it necessary to store Levocarnitine in the refrigerator?

No, all forms of Levocarnitine must be stored at controlled room temperature, typically between 20 C and 25 C. Official storage requirements specify protecting the medicine from freezing.


Q: What are the signs of a possible allergic reaction to Levocarnitine?

Serious hypersensitivity reactions have been reported, primarily following intravenous administration. Signs mentioned in official documents include anaphylaxis, swelling of the throat (laryngeal edema), and difficulty breathing (bronchospasm).


Q: Does Levocarnitine interact with caffeine or alcohol?

Official regulatory information states explicitly that there are no documented interaction patterns with food, drinks, or alcohol. The documents do not list a specific interaction with caffeine.


Q: If I am a vegetarian, do I need Levocarnitine more?

Levocarnitine is naturally synthesized in the body, but it is also predominantly obtained from food sources, mainly animal products. Studies indicate that diets that exclude these sources, such as vegetarian or vegan diets, typically result in lower amounts of carnitine being consumed.


Q: What kind of monitoring is needed while taking Levocarnitine?

Monitoring is necessary to ensure safety and effectiveness. This includes periodic assessment of plasma free carnitine levels to help guide dose adjustments. Specific monitoring is also required for certain patients, such as coagulation status for those taking Warfarin, and blood glucose levels for diabetic patients.


Q: Is it true that Levocarnitine is naturally found in some foods?

Yes, Levocarnitine is described as a naturally occurring substance that the body requires. While the drug itself is synthetically produced, the compound L-carnitine is found in food sources, primarily animal products such as red meat and dairy.


Q: Can elderly patients use Levocarnitine without increased risk?

Official regulatory documents state that no specific restrictions or increased risks are noted for the geriatric population (older patients). However, monitoring is required for all patient groups.


Q: Can Levocarnitine be given through a feeding tube?

The oral solution administration guidance notes that it may be consumed alone or dissolved in a drink or other liquid food.


Q: Are there specific dietary requirements while taking Levocarnitine?

Yes, the oral dosage form is required to be taken during or immediately following meals. This timing is specified in regulatory documents to optimize drug absorption and improve patient tolerance.


Q: What evidence exists for Levocarnitine use in heart-related conditions?

Official documents highlight that the drug's energy-enhancing mechanism affects high-energy-demand tissues, including the myocardium (heart muscle). Due to this mechanism, research has examined its potential for use in heart-related conditions, such as heart failure.


Q: How is Levocarnitine dosage determined?

Dosage is initially determined by the patient's body weight or by fixed doses. The final dose is then adjusted and maintained based on the patient's clinical response and periodic monitoring of plasma free carnitine levels within the therapeutic range.

How should Levocarnitine be stored and disposed of?

How to Store and Dispose of Levocarnitine?

Regulatory documents define specific storage and handling requirements for Levocarnitine, including the oral solution, tablets, and sterile injection.


Storage Requirements

Levocarnitine must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It is mandatory to keep the medicine in a closed container and protect it from excessive heat.

  • Do not freeze any Levocarnitine formulation.
  • The sterile injection solution must also be protected from light and kept in its original carton until use.
  • Keep all forms of the medicine out of the reach of children.

Stability and Disposal

The preservative-free injection vial requires that any unused portion of an opened vial must be discarded. A diluted solution prepared for infusion is stable for up to 24 hours at room temperature.

Disposal of any expired or unused Levocarnitine product must be completed in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levocarnitine found in:

A-Z Index: